Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
July 16, 2018updated 17 Jul 2018 10:17am

NICE warns of overprescribing antibiotics for pulmonary disease

NICE has released a draft guidance to restrict antibiotic use in patients diagnosed with chronic obstructive pulmonary disease (COPD).

By GBI Research

NICE has released a draft guidance to restrict antibiotic use in patients diagnosed with chronic obstructive pulmonary disease (COPD).

This suggests that in many cases treatment has not been appropriate, which could ultimately lead to a higher risk of antimicrobial resistance.

COPD is a common life-threatening disease producing 115,000 hospital visits annually and affecting 3 million people in the UK, 2 million of which are undiagnosed.

NICE guidelines say that antibiotics should be used for treatment only if patients experience severe flare-ups of symptoms.

In the guidance NICE reported that acute exacerbations of COPD could be due to a range of factors, not just viral infections and smoking.

Half of acute exacerbations of COPD may be the result of bacterial infections.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
The powerful networks advancing life sciences in Charleston | USA
The power of infrastructure: How Charleston | SC | USA is expanding horizons for life science companies

Hence, the other half which are non-bacterial infections will not respond to antibiotics.

Healthcare professionals believe that there are limited benefits to utilising antibiotics for the management of acute exacerbations of COPD and believe there are more effective treatment options than antibiotics.

The revised guidelines will permit healthcare professionals to carry out responsible decisions to help patients manage their condition and lower the risk of resistant infections.

For more insight and data, visit the GBI Research report store.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU